Oxyquinoline is a medication used in combination with other medications to restore vaginal pH.
- Brand Names
- Fem Ph, Relagard
- Generic Name
- DrugBank Accession Number
Oxyquinoline is a heterocyclic phenol and derivative of quinoline with antiseptic, disinfectant, and pesticide properties. It is used as a stabilizer for hydrogen peroxide, where it is sometimes added in cosmetic products.
- Small Molecule
- Approved, Vet approved
- Average: 145.158
- Chemical Formula
- External IDs
Oxyquinoline is used as a biocidal component of several over the counter products. These products are marketed for the purposes of inhibiting abnormal biological growth in the vagina and restoring natural pH.Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.
- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
Oxyquinoline acts as a biocide to eliminate bacteria and fungi 1.
- Mechanism of action
The mechanism by which oxyquinoline exerts its biocidal effect is unknown.
- Volume of distribution
- Protein binding
In the urine, 60% of the dose is excreted as glucuronide conjugates and 23% of the dose as sulfate conjugates 1. In the bile, 9% of the total dose is found as glucuronide conjugates.
Hover over products below to view reaction partners
- Route of elimination
Oxyquinoline is excreted in both the primarily in the urine with some in the bile 1.
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Abacavir Abacavir may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Oxyquinoline which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. Aclidinium Aclidinium may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. Acrivastine Acrivastine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. Acyclovir Acyclovir may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more
- Food Interactions
- No interactions found.
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key 8-Hydroxyquinoline citrate K522O2O40B 134-30-5 GTOQWWQKBBZILU-UHFFFAOYSA-N 8-Hydroxyquinoline hydrochloride Not Available 16862-11-6 GXBJNMSTHMBPPE-UHFFFAOYSA-N 8-Hydroxyquinoline salicylate 98Z1AMM4PS 2439-07-8 GOEKBPHGLUYFOX-UHFFFAOYSA-N 8-Hydroxyquinoline sulfate Not Available 1130-05-8 MRUMAIRJPMUAPZ-UHFFFAOYSA-N Oxyquinoline sulfate 61VUG75Y3P 134-31-6 YYVFXSYQSOZCOQ-UHFFFAOYSA-N
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Arkodyne Oxyquinoline sulfate (3 mg / loz) + Benzalkonium chloride (1.5 mg / loz) + Benzocaine (4 mg / loz) Lozenge Oral Laboratoire Romilo 1980-12-31 1999-08-18 New Skin Clear Liquid Bandage Oxyquinoline (1 %) + Clove oil (.8 %) Liquid Topical Medtech Laboratories, Inc. 1969-12-31 1998-07-08 New Skin Clear Spray Bandage Oxyquinoline (1 %) + Clove oil (.8 %) Aerosol Topical Medtech Laboratories, Inc. 1969-12-31 1998-07-08 Racestyptine Cord Oxyquinoline sulfate (.24 mg / 100 cm) + Aluminum chloride (60 mg / 100 cm) + Lidocaine (35 mg / 100 cm) Packing Dental Septodont 1981-12-31 2000-08-03 Racestyptine Sol Oxyquinoline sulfate (100 mg / 100 mL) + Aluminum chloride (25 g / 100 mL) Liquid Dental Septodont 1977-12-31 2017-07-07 Sulpak II Oxyquinoline sulfate (.1 %) + Aluminum chloride (25 %) Liquid Dental North Pacific Dental Inc. 1983-12-31 1997-12-22 Trimo San Deodorant Vaginal Jelly Oxyquinoline sulfate (0.025 %) + Boric acid (1.0 %) + Sodium borate (0.7 %) Jelly Vaginal Milex Products Ltd. 1979-12-31 2005-07-25
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Fem pH Oxyquinoline sulfate (0.00025 g/1g) + Acetic acid (0.009 g/1g) Jelly Vaginal Pharmics, Inc. 1999-07-15 Not applicable Relegard Oxyquinoline (0.025 mg/1mL) + Acetic acid (0.9 mg/1mL) Gel Topical Blansett Pharmacal Co 2017-03-20 Not applicable Trimo San Oxyquinoline sulfate (0.25 mg/1g) + Sodium lauryl sulfate (0.1 mg/1g) Jelly Vaginal CooperSurgical, Inc. 1977-04-01 Not applicable Trimo-San Oxyquinoline sulfate (0.25 mg/1g) + Sodium lauryl sulfate (0.1 mg/1g) Jelly Vaginal Denison Pharmaceuticals, Llc 2019-09-16 Not applicable
- ATC Codes
- R02AA14 — OxyquinolineA01AB07 — Oxyquinoline
- A01AB — Antiinfectives and antiseptics for local oral treatment
- A01A — STOMATOLOGICAL PREPARATIONS
- A01 — STOMATOLOGICAL PREPARATIONS
- A — ALIMENTARY TRACT AND METABOLISM
- D08AH — Quinoline derivatives
- D08A — ANTISEPTICS AND DISINFECTANTS
- D08 — ANTISEPTICS AND DISINFECTANTS
- D — DERMATOLOGICALS
- Drug Categories
- Alimentary Tract and Metabolism
- Anti-Infective Agents, Local
- Antiinfectives and Antiseptics for Local Oral Treatment
- Antiseptics and Disinfectants
- Drugs that are Mainly Renally Excreted
- Genito Urinary System and Sex Hormones
- Gynecological Antiinfectives and Antiseptics
- Heterocyclic Compounds, Fused-Ring
- Quinoline Derivatives
- Stomatological Preparations
- Throat Preparations
- Chemical TaxonomyProvided by Classyfire
- This compound belongs to the class of organic compounds known as 8-hydroxyquinolines. These are compounds containing a quinoline moiety, which carries a hydroxy group at the 8-position. Quinoline consists of a benzene ring fused to a pyrimidine ring to form benzo[b]azabenzene.
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Quinolines and derivatives
- Sub Class
- Direct Parent
- Alternative Parents
- 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Pyridines and derivatives / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Hydrocarbon derivatives
- 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / 8-hydroxyquinoline / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Heteroaromatic compound / Hydrocarbon derivative / Organic nitrogen compound / Organic oxygen compound
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- monohydroxyquinoline (CHEBI:48981) / a small molecule (8-HYDROXYQUINOLINE)
- Affected organisms
- Aspergillis, Candida and other fungi
- Trichomonas vaginalis, Giardia duodenalis, and Entamoeba histolytica
- Pseudomonas aeruginosa
- Escherichia coli
- Staphylococcus aureus
- Klebsiella pneumoniae
- Pseudomonas fluorescens
- Pseudomonas cepacia
- Penicillium notatum
- CAS number
- InChI Key
- IUPAC Name
- Synthesis Reference
International Agency for Research on Cancer (IARC). 1977. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, vol. 13, pages 101-112 . Lyon, IARC.
- General References
- PDB Entries
- 3kcy / 3vh9 / 4jfg
- Clinical Trials
Phase Status Purpose Conditions Count 4 Recruiting Treatment Bacterial Vaginosis (BV) / Vaginal Discharge / Vaginosis 1 2, 3 Completed Prevention Bacterial Vaginosis (BV) 1 1 Not Yet Recruiting Diagnostic Fibromyalgia (FM) / Healthy Subjects (HS) / Multiple Sclerosis / Myalgic Encephalomyelitis (ME) 1
- Not Available
- Not Available
- Dosage Forms
Form Route Strength Lozenge Oral Injection, solution Intravenous Liquid Topical Aerosol Topical Packing Dental Gel Topical Liquid Dental Jelly Vaginal Cream Topical
- Not Available
- Not Available
- Experimental Properties
Property Value Source melting point (°C) 76 Andersen A: Final amended report on the safety assessment of oxyquinoline and oxyquinoline sulfate as used in cosmetics. Int J Toxicol. 2006;25 Suppl 1:1-9. boiling point (°C) 267 Andersen A: Final amended report on the safety assessment of oxyquinoline and oxyquinoline sulfate as used in cosmetics. Int J Toxicol. 2006;25 Suppl 1:1-9. water solubility Insoluble Andersen A: Final amended report on the safety assessment of oxyquinoline and oxyquinoline sulfate as used in cosmetics. Int J Toxicol. 2006;25 Suppl 1:1-9. pKa 5.017
- Predicted Properties
Property Value Source Water Solubility 4.18 mg/mL ALOGPS logP 1.91 ALOGPS logP 1.83 ChemAxon logS -1.5 ALOGPS pKa (Strongest Acidic) 9.36 ChemAxon pKa (Strongest Basic) 4.83 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 33.12 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 41.96 m3·mol-1 ChemAxon Polarizability 14.87 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon
- Predicted ADMET Features
- Not Available
- Mass Spec (NIST)
- Not Available
Spectrum Spectrum Type Splash Key GC-MS Spectrum - EI-B GC-MS splash10-00kb-4900000000-dbee61b764231929582e GC-MS Spectrum - EI-B GC-MS splash10-00kb-8900000000-9f44d33e560065cf0670 Mass Spectrum (Electron Ionization) MS splash10-00kb-6900000000-884423812367e06a25fa Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-ITFT , positive LC-MS/MS splash10-014i-0900000000-98366904cdd9ed4a8caa 1H NMR Spectrum 1D NMR Not Applicable 13C NMR Spectrum 1D NMR Not Applicable
Drug created on December 03, 2015 16:51 / Updated on February 21, 2021 18:52